DSGN trades 81.0% below Wall Street's consensus target of $22.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DSGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Design Therapeutics, Inc. (DSGN) has a Wall Street consensus price target of $22.33, based on estimates from 7 covering analysts. With the stock currently trading at $12.34, this represents a potential upside of +81.0%. The company has a market capitalization of $771M.
Analyst price targets range from a low of $20.00 to a high of $26.00, representing a 27% spread in expectations. The median target of $21.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, DSGN trades at a trailing P/E of -10.1x. Analysts expect EPS to grow -17.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FULCFulcrum Therapeutics, Inc. | $200M | $3.69 | $3.60 | -2.4% | Buy | — | 17 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.1B | $25.16 | $38.00 | +51.0% | Buy | 50.6x | 12 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.50 | $59.50 | +142.9% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $402M | $2.62 | $4.50 | +71.8% | Buy | — | 26 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.43 | $67.83 | +22.4% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.26 | $23.00 | +87.6% | Buy | — | 39 |
 PRMEPrime Medicine, Inc. | $538M | $2.98 | $7.50 | +151.7% | Buy | — | 10 |
 ILMNIllumina, Inc. | $41.3B | $273.04 | $237.00 | -13.2% | Buy | 51.0x | 50 |
Quick answers to the most common questions about buying DSGN stock.
The consensus Wall Street price target for DSGN is $22.33, representing 81.0% upside from the current price of $12.34. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DSGN has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $22.33 implies 81.0% upside from current levels.
DSGN's current price is $12.34 with a consensus target of $22.33 (81.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $26 for DSGN, while the most conservative target is $20. The consensus of $22.33 represents the median expectation. These targets typically reflect 12-month expectations.
DSGN is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DSGN stock forecast based on 7 Wall Street analysts shows a consensus price target of $22.33, with estimates ranging from $20 (bear case) to $26 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DSGN, with a "Buy" consensus rating and $22.33 price target (81.0% upside). 4 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DSGN analyst price targets range from $20 to $26, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $22.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.